Developed by Glaukos, the iDose TR (travoprost intraocular implant) 75 mcg is a new, FDA-approved treatment that is designed ...

Paul Badawi, Founder and CEO of Sight Sciences and Leon Herndon, MD, Duke University Eye Center, Durham, NC, commented on the ...

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

SpyGlass Pharma reports positive 36-month first-in-human and 3-month phase I/II trial results for its novel BIM-IOL System: Aliso Viejo, California Wednesday, November 12, 2025, 1 ...

Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of ...

Trial at 36 Months: 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops100% of evaluable patients ...

University of Missouri researchers have discovered two potential biomarkers of glaucoma – agmatine and thiamine ...

Sight Sciences’ management is scheduled to present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 am PT / 11:20 am ET. Sight Sciences’ management is scheduled to ...

"OMNI continues to deliver results for patients, whether it be patients undergoing cataract surgery, those that have already had cataract surgery and are now pseudophakic, or groups at historically ...

Through 24 months, scleral bio-reinforced cyclodialysis combined with cataract surgery lowered IOP by enhancing uveoscleral outflow, according to a study published in Ophthalmology Science. "The ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...